Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of ensifentrine in moderate to severe chronic obstructive pulmonary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Ensifentrine (ensifentrine)

Snippet

Sponsor: Nuance Pharma (shanghai) Co., Ltd | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED